ERYtech Pharma Announces That It Has Started a Phase II Clinical Trial with GRASPA(R) as First-Line Treatment among Patients with Acute Lymphoblastic Leukaemia (ALL) Aged 55 and Older
LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces that it has started a phase II clinical trial with GRASPA® as first-line treatment among patients with acute lymphoblastic leukaemia (ALL) aged 55 and older. A first cohort of 3 patients has already been recruited.